02-11-2012
Questionnaires are often used in clinical and nutritional research to subjectively evaluate the effect of an intervention on an outcome measure or e.g. to select a study population with specific characteristics from a larger pool of potential study participants. Nevertheless, their thoughtless application in health claim-targeted studies have frequently resulted in EFSA dismissing the outcomes generated by these questionnaires. Validation […]
>> read more
NutriClaim to present on Probiotic Claims at Health Claim Conference
23-10-2011
During the upcoming 7th International Workshop Nutrition & Health Claims Europe, NutriClaim will shed its light on why, up till now, all health claim submissions for probiotics have received a negative opinion from EFSA. The presentation will focus on art. 13.5 and 14 health claims evaluations, primarily pertaining to gastrointestinal and immune health benefits of probiotics. For the full program: […] >> read more
During the upcoming 7th International Workshop Nutrition & Health Claims Europe, NutriClaim will shed its light on why, up till now, all health claim submissions for probiotics have received a negative opinion from EFSA. The presentation will focus on art. 13.5 and 14 health claims evaluations, primarily pertaining to gastrointestinal and immune health benefits of probiotics. For the full program: […] >> read more
Will EFSA accept that Bifidobacterium BB-12 really improves immune function?
07-10-2011
Recently, Rizzardini et al. (B. J. Nutr. 2011) showed that in a vaccination model in healthy subjects supplementation with either Bifidobacterium BB-12 or Lactobacillus casei 431 resulted in significantly greater mean fold increases in total and vaccine-specific antibody titers. However, the question remains whether the observed and statistically significant differences will also be perceived as physiologically relevant by EFSA in […] >> read more
Recently, Rizzardini et al. (B. J. Nutr. 2011) showed that in a vaccination model in healthy subjects supplementation with either Bifidobacterium BB-12 or Lactobacillus casei 431 resulted in significantly greater mean fold increases in total and vaccine-specific antibody titers. However, the question remains whether the observed and statistically significant differences will also be perceived as physiologically relevant by EFSA in […] >> read more